Abstract
OBJECTIVE To determine whether immune protein panels add significant information to correlates of cognition.
BACKGROUND Immune mechanisms in vascular cognitive impairment and dementia are incompletely characterized.
DESIGN/METHODS A subsample of the prospective Northern Manhattan Study underwent detailed neuropsychological testing. Cognitive scores were converted into Z-scores and categorized into four domains (memory, language, processing speed, and executive function) based on factor analysis. Blood samples were analyzed using a 60-plex immunoassay. We used least absolute shrinkage and selection operator (LASSO) procedures to select markers and their interactions independently associated with cognitive scores. Linear regression models assessed cross-sectional associations of known correlates of cognition with cognitive scores, and assessed model fit before and after addition of LASSO-selected immune markers.
RESULTS Among 1179 participants (mean age 70±8.9 years, 60% women, 68% Hispanic), inclusion of LASSO-selected immune markers improved model fit above age, education, and other risk factors (p for likelihood ratio test<0.005 for all domains). C-C Motif Chemokine Ligand 11 (CCL 11, eotaxin), C-X-C Motif Chemokine Ligand 9 (CXCL9), hepatocyte growth factor (HGF), and serpin E1 (plasminogen activator inhibitor-1) were associated with each of the domains and with overall cognitive function. Immune marker effects were comparable to conventional risk factors: for executive function, each standard deviation (SD) increase in CCL11 was associated with an effect equivalent to aging three years; for memory, HGF had twice the effect of aging.
CONCLUSIONS Immune markers associate with cognitive function in a multi-ethnic cohort. Further work is needed to validate these findings and determine optimal treatment targets.
Competing Interest Statement
Dr. Elkind receives royalties from UpToDate for chapters on stroke and COVID-19. Ms. Moon declares no conflicts of interest. Dr. Cheung declares no conflicts of interest. Dr. Sacco declares no conflict of interest. Dr. Hornig declares no conflict of interest. Dr. Rundek declares no conflict of interest.
Funding Statement
Source of funding: NIH/NINDS R01 NS029993 Authors received no payment or services from any other third party for any aspect of the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Columbia University Institutional Review Board 154 Haven Avenue, 1st Floor New York, NY 10032 +1 212 342 1218
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Source of funding: NIH/NINDS R01 NS029993
Initially presented at American Academy of Neurology Annual Meeting May 2018.
Conflicts of Interest: Dr. Elkind receives royalties from UpToDate for chapters on stroke and COVID-19.
Ms. Moon declares no conflicts of interest.
Dr. Cheung declares no conflicts of interest.
Dr. Sacco declares no conflict of interest.
Dr. Hornig declares no conflict of interest.
Dr. Rundek declares no conflict of interest.
Data Availability
Data are available upon appropriate request to the principal investigators.
Non-standard Abbreviations and Acronyms
- 95%CI
- 95% confidence interval
- AD
- Alzheimer Disease
- CCL2
- C-C Motif Chemokine Ligand 2
- CCL3
- C-C Motif Chemokine Ligand 3
- CCL5
- C-C Motif Chemokine Ligand 5
- CCL11
- C-C Motif Chemokine Ligand 11
- CSF3
- Colony stimulating factor 3
- CRP
- C-reactive protein
- CXCL9
- C-X-C Motif Chemokine Ligand 9
- CXCL10
- C-X-C Motif Chemokine Ligand 10
- HGF
- hepatocyte growth factor
- IL12p40
- interleukin-12 p40
- IL1RA
- interleukin-1 receptor antagonist
- LASSO
- Least Absolute Shrinkage and Selection Operator
- LRT
- likelihood ratio test
- MCI
- mild cognitive impairment
- NOMAS
- Northern Manhattan Study
- SCF
- stem cell factor
- sFasL
- soluble Fas ligand
- TNFβ
- tumor necrosis factor β
- TRAIL
- tumor necrosis factor-related apoptosis-inducing ligand
